The drug is nucresiran, a silencer. It is also known as the trition cm study. It is a double blind placebo controlled study with a 66% chance that you receive the drug. The placebo is normal saline.
October 13
Great question! It sounds like you may be referring to a clinical trial involving a medication — possibly one being studied for amyloidosis. The name "nucreserine" doesn't closely match any currently known amyloidosis treatments or trials in available information, so it's worth double-checking the exact spelling or name Show Full Answer
Great question! It sounds like you may be referring to a clinical trial involving a medication — possibly one being studied for amyloidosis. The name "nucreserine" doesn't closely match any currently known amyloidosis treatments or trials in available information, so it's worth double-checking the exact spelling or name with your trial coordinator.
To answer your broader question about Attruby — yes, it is a stabilizer! Here's a quick breakdown:
- Attruby (acoramidis) is a TTR stabilizer, meaning it works by binding to the TTR protein and preventing it from breaking apart
- When TTR breaks apart, it forms harmful amyloid deposits that build up in the heart
- By keeping the protein stable, Attruby helps slow disease progression
- It is FDA-approved for ATTR cardiomyopathy (both wild-type and hereditary forms)
- It's taken as a tablet, twice daily
Since you're currently in a double-blind trial (meaning neither you nor your doctors know if you're getting the real drug or placebo), it's completely normal to be unsure what you're receiving — that's actually how these trials are designed to work to ensure unbiased results.
It would be worth asking your trial team whether the investigational drug you're on is a stabilizer or works differently, as they can share that general information without breaking the blind.
October 13
Join
Your Privacy Choices
